Bayer is pressing ahead with a phase 3 trial of its oral Factor XIa inhibitor asundexian, a new anticoagulant, despite missing efficacy targets in two mid-stage studies. The OCEANIC trial ...

Bayer has decided to discontinue a phase 3 trial of its oral Factor XIa inhibitor asundexian in patients with atrial fibrillation (AF), after an interim analysis concluded the novel anticoagulant ...

Indeed, the recent discontinuation of the phase 3 OCEANIC-AF trial, which compared the factor XIa inhibitor asundexian (Bayer) to the DOAC apixaban (Eliquis, Bristol Myers Squibb/Pfizer ...

Bayer reported that ... The failure of a late-stage study on asundexian was a major setback for the company. In the past 30 days, NVO’s EPS estimate for 2025 has increased to $3.93 from $3 ...

Successful drug development is imperative to Bayer amid multiple challenges. The failure of a late-stage study on asundexian was a major setback for the company. BAYRY is also working to expand ...

Less Severe Strokes With LAA Closure vs DOAC in AF? Atrial fibrillation treated with left atrial appendage closure was associated with ischemic strokes that were less severe than those among ...

In the OCEANIC-AF trial, asundexian resulted in a small increase in the rates of stroke and lowered bleeding compared with apixaban in patients with atrial fibrillation (AF) who were naive to oral ...

Shares of pharma conglomerate Bayer BAYRY were down 7.1% on March 24, following a setback in the ongoing Roundup Litigation. Bayer reported that, on March 21, the jury at the Barnes Roundup trial ...

BERLIN (Reuters) -Bayer was ordered by a jury in the U.S. state of Georgia to pay about $2.1 billion to a plaintiff who claimed the company's Roundup weed killer caused his cancer, the plaintiff's ...

A jury in the US state of Georgia has ordered the multinational chemical company Bayer to pay $2.1 billion to a plaintiff who claimed its Roundup weed killer caused his cancer, the plaintiff’s ...

Bayer's stock surged 24.5% since December 2024, yet remains a speculative investment due to significant risks like high debt and ongoing litigation. 2024 annual results showed a 2.2% sales decline ...

Bayer was ordered by a jury in Georgia to pay about $2.1 billion to a plaintiff who claimed the company's Roundup weed killer caused his cancer, the plaintiff's law firms said on Friday.